{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-337986","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2026-08-06T20:09:11+00:00","discovered_at":"2026-08-06T20:11:31.330108+00:00","generated_at":"2026-08-06T20:12:09.583281+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artiva Q2 net loss $25M; cash $349.4M; RMAT granted; Phase 3 RA trial to start H2 2026","bullets":["Cash, cash equivalents and investments of $349.4M as of June 30, 2026, expected to fund operations into 2029.","Net loss of $25.0M for Q2 2026 vs $21.3M for Q2 2025; R&D expenses $21.9M vs $17.9M.","FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory RA.","Phase 3 randomized controlled trial of AlloNK plus rituximab vs rituximab alone in ~150 RA patients to start H2 2026.","Completed ~$300M underwritten offering in May 2026; appointed Diego Miralles, M.D., as president and head of R&D."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-337986","json":"https://secwatch.observer/filing/0001193125-26-337986.json","markdown":"https://secwatch.observer/filing/0001193125-26-337986.md","text":"https://secwatch.observer/filing/0001193125-26-337986.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526337986/0001193125-26-337986-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526337986/artv-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:12:09.583281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}